Corpseed

CDSCO Launches Digital Monitoring for High-Risk Solvents

Department: DGHSAuthority: CDSCOPublish: Applicable: 23-10-2025Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use โ€œOpen PDFโ€ for full screen view.

Schedule a Call Back

IN +91

2,100+ CDSCO medical device assignments since 2018

Clients include Endolite India, Mankind Pharma, Ossur India, ADK Health Care, Credence Prosthetic India, V2U Physio Asia, International Electro Medical Company, Radimage Healthcare India, Istok New Hearing AID, Simpladent Implant Solutions, Starkey Laboratories India, Gentec Medical (12 of 1,100+ served since 2018).

A few more clients we've served in this industry
Pharma and healthcare
Endolite India ยท Mankind Pharma ยท Ossur India ยท ADK Health Care ยท Credence Prosthetic India ยท V2U Physio Asia ยท International Electro Medical Company ยท Radimage Healthcare India ยท Istok New Hearing AID ยท Simpladent Implant Solutions ยท Starkey Laboratories India ยท Gentec Medical ยท Cureesse Pharma ยท Hygiene Medicus ยท Nexus Surgical and Medicare
More clients
Meditronix Corporation ยท Nilkamal ยท Haesi GHL ยท GHL ยท Servotech Power Systems ยท Elektrocraft India ยท Happy Medicare ยท Anantaa Gsk Innovations ยท Cogmac Technologies ยท Aficionados Tech ยท Superceuticals ยท Truevis Technologies ยท 1008 Digital Health ยท BDS Services ยท Evoq Imaging Technologies ยท Premier Medical Systems and Devices ยท Riransa ยท Vitrag Infra Projects ยท Insta Biotech ยท Digital Acoustics ยท Artificial Learning Systems India ยท Nfilade Security Solutions ยท Humors Tech ยท K2O Consulting
See our CDSCO medical device service โ†’

Summary

The Central Drugs Standard Control Organisation (CDSCO) has launched a Digital Monitoring System through its Online National Drug Licensing System (ONDLS) portal to strengthen oversight of high-risk pharmaceutical solvents. This initiative, communicated via a letter dated October 22, 2025, responds to recent safety concerns, including the detection of Diethylene Glycol (DEG) in cough syrups, which posed major public health risks.

Following a high-level meeting chaired by the Union Health Secretary on October 5, 2025, the CDSCO has authorized strict compliance for solvent manufacturers. All manufacturers must now obtain or register their licenses on the ONDLS portal, with existing licensees submitting their current data through the โ€œOld Licence Managementโ€ section. Additionally, batch-wise details, including quantity produced, Certificate of Analysis (CoA), and buyer information, must be uploaded.

State and UT Drug Controllers are directed to ensure no high-risk solvent batch reaches the market without adherence to these requirements. The updated ONDLS portal is fully operational to secure the pharmaceutical supply chain and protect product quality.

Document Preview

Embedded reference document

Fullscreen โ†—

Related

Explore more updates from the same department.

Call